A Phase 1 Study of GNR-051 in Subjects With Advanced Malignancies

PHASE1Active, not recruitingINTERVENTIONAL
Enrollment

48

Participants

Timeline

Start Date

July 22, 2020

Primary Completion Date

November 7, 2022

Study Completion Date

January 31, 2025

Conditions
Carcinoma, Non-Small-Cell LungCarcinoma, Renal CellMelanoma
Interventions
BIOLOGICAL

GNR-051

Anti-PD1 monoclonal antibody

Trial Locations (12)

115478

"FSBI N.N. Blokhin National Medical Research Center of Oncologyof the Ministry of Health of the Russian Federation", Moscow

117997

"FSBI Russian Scientific Center of Roentgenoradiology of the Ministry of Health of the Russian Federation", Moscow

119991

"FSAEI HE I.M. Sechenov First Moscow State Medical University of the Ministry of Health of Russian Federation", Moscow

123056

"JSC MEDSI Group of Companies", Moscow

125367

"FSII Treatment and Rehabilitation Center of the Ministry of Health of the Russian Federation", Moscow

188663

"SBHI Leningrad Regional Clinical Oncology Dispensary", Saint Petersburg

190013

"JSC Modern Medical Technologies", Saint Petersburg

197022

"FSAEI HE I.P. Pavlov First Saint Petersburg State Medical University of the Ministry of Health of the Russian Federation", Saint Petersburg

197758

"FSBI N.N. Petrov National Medical Research Center of Oncology of the Ministry of Healthcare of the Russian Federation", Moscow

"SBHI St. Petersburg Clinical Scientific and Practical Center for Specialized Types of Medical Care (Oncological)", Saint Petersburg

198035

"LLC Tentanda Via", Saint Petersburg

420029

"SAHI Republican Clinical Oncological Dispensary of the Ministry of Health of the Republic of Tatarstan", Kazan'

All Listed Sponsors
lead

AO GENERIUM

INDUSTRY